دورية أكاديمية
Single-shot dendritic cell targeting SARS-CoV-2 vaccine candidate induces broad, durable and protective systemic and mucosal immunity in mice.
| العنوان: | Single-shot dendritic cell targeting SARS-CoV-2 vaccine candidate induces broad, durable and protective systemic and mucosal immunity in mice. |
|---|---|
| المؤلفون: | Cheang NYZ; Infectious Diseases Translational Research Programme, Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore., Tan KS; Infectious Diseases Translational Research Programme, Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Tan PS; Monash Biomedicine Discovery Institute & Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia., Purushotorma K; Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore; Immunology Translational Research Programme, Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Yap WC; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore., Tullett KM; Monash Biomedicine Discovery Institute & Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia., Chua BYL; Immunology Translational Research Programme, Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Yeoh AY; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore., Tan CQH; Histology Core Facility, Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore., Qian X; Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore; Immunology Translational Research Programme, Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Chen H; Infectious Diseases Translational Research Programme, Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Tay DJW; Infectious Diseases Translational Research Programme, Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Caminschi I; Monash Biomedicine Discovery Institute & Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia; Department of Microbiology and Immunology, Peter Doherty Institute, The University of Melbourne, Melbourne, VIC, Australia., Tan YJ; Infectious Diseases Translational Research Programme, Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Macary PA; Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore; Immunology Translational Research Programme, Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Tan CW; Infectious Diseases Translational Research Programme, Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Lahoud MH; Monash Biomedicine Discovery Institute & Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia., Alonso S; Infectious Diseases Translational Research Programme, Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore. Electronic address: micas@nus.edu.sg. |
| المصدر: | Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2024 Jul 03; Vol. 32 (7), pp. 2299-2315. Date of Electronic Publication: 2024 May 06. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Cell Press Country of Publication: United States NLM ID: 100890581 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-0024 (Electronic) Linking ISSN: 15250016 NLM ISO Abbreviation: Mol Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2017- : Cambridge, MA : Cell Press Original Publication: San Diego, CA : Academic Press, 2000- |
| مواضيع طبية MeSH: | Dendritic Cells*/immunology , SARS-CoV-2*/immunology , COVID-19*/prevention & control , COVID-19*/immunology , COVID-19*/virology , Immunity, Mucosal* , COVID-19 Vaccines*/immunology , Lectins, C-Type*/immunology , Lectins, C-Type*/metabolism , Antibodies, Viral*/immunology , Antibodies, Neutralizing*/immunology, Animals ; Mice ; Humans ; Female ; Spike Glycoprotein, Coronavirus/immunology ; Receptors, Mitogen/immunology ; Antibody-Dependent Cell Cytotoxicity/immunology ; Receptors, Immunologic |
| مستخلص: | Current coronavirus disease 2019 vaccines face limitations including waning immunity, immune escape by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, limited cellular response, and poor mucosal immunity. We engineered a Clec9A-receptor binding domain (RBD) antibody construct that delivers the SARS-CoV-2 RBD to conventional type 1 dendritic cells. Compared with non-targeting approaches, single dose immunization in mice with Clec9A-RBD induced far higher RBD-specific antibody titers that were sustained for up to 21 months after vaccination. Uniquely, increasing neutralizing and antibody-dependent cytotoxicity activities across the sarbecovirus family was observed, suggesting antibody affinity maturation over time. Consistently and remarkably, RBD-specific follicular T helper cells and germinal center B cells persisted up to 12 months after immunization. Furthermore, Clec9A-RBD immunization induced a durable mono- and poly-functional T-helper 1-biased cellular response that was strongly cross-reactive against SARS-CoV-2 variants of concern, including Omicron subvariants, and with a robust CD8 + T cell signature. Uniquely, Clec9A-RBD single-shot systemic immunization effectively primed RBD-specific cellular and humoral immunity in lung and resulted in significant protection against homologous SARS-CoV-2 challenge as evidenced by limited body weight loss and approximately 2 log Competing Interests: Declaration of interests M.H.L., I.C., and K.M.T. are listed as inventors on patents relating to Clec9A antibodies. (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.) |
| References: | Eur J Immunol. 2022 Aug;52(8):1297-1307. (PMID: 35416291) Lancet. 2020 Mar 28;395(10229):1054-1062. (PMID: 32171076) Sci Immunol. 2022 Dec 23;7(78):eabp8328. (PMID: 35549298) Infect Immun. 2014 Jan;82(1):10-20. (PMID: 24101691) J Hematol Oncol. 2021 Feb 27;14(1):38. (PMID: 33640005) Cell Rep Med. 2022 Nov 15;3(11):100793. (PMID: 36257326) Mucosal Immunol. 2022 Apr;15(4):745-761. (PMID: 35418673) Immunity. 2012 Apr 20;36(4):646-57. (PMID: 22483802) Immunity. 2017 Mar 21;46(3):504-515. (PMID: 28329707) Clin Transl Immunology. 2022 Aug 09;11(8):e1410. (PMID: 35957961) NPJ Vaccines. 2017 Nov 6;2:31. (PMID: 29263886) J Immunother Cancer. 2020 Jul;8(2):. (PMID: 32737142) Science. 2021 Dec 03;374(6572):abm0829. (PMID: 34648302) Nature. 2022 Sep;609(7929):998-1004. (PMID: 36131022) Trends Immunol. 2021 Nov;42(11):956-959. (PMID: 34580004) Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16472-7. (PMID: 25267651) Cell Rep. 2021 Aug 24;36(8):109591. (PMID: 34433030) Sci Immunol. 2022 May 20;7(71):eabo1303. (PMID: 35324269) Immunology. 2017 Oct;152(2):185-194. (PMID: 28628194) JCI Insight. 2016 May 19;1(7):e87102. (PMID: 27699265) Science. 2007 Jan 5;315(5808):107-11. (PMID: 17204652) Science. 2022 Nov 11;378(6620):619-627. (PMID: 36264829) J Immunol. 2020 Oct 1;205(7):1842-1856. (PMID: 32839238) Clin Transl Med. 2022 Apr;12(4):e802. (PMID: 35415890) Front Immunol. 2014 May 22;5:239. (PMID: 24904587) Nat Immunol. 2022 Feb;23(2):186-193. (PMID: 35105982) J Exp Med. 2007 May 14;204(5):1095-106. (PMID: 17438065) Elife. 2020 Dec 02;9:. (PMID: 33264090) Mucosal Immunol. 2022 Apr;15(4):584-594. (PMID: 35505121) J Exp Med. 2000 Dec 18;192(12):1685-96. (PMID: 11120766) Immunity. 2012 Apr 20;36(4):635-45. (PMID: 22483800) Hum Vaccin Immunother. 2022 Dec 31;18(1):1873056. (PMID: 33625943) Am J Respir Cell Mol Biol. 2017 Feb;56(2):152-159. (PMID: 27767327) N Engl J Med. 2022 Nov 3;387(18):1716-1718. (PMID: 36223534) Immunity. 2020 Oct 13;53(4):724-732.e7. (PMID: 32783919) Nat Immunol. 2022 Feb;23(2):194-202. (PMID: 35105985) Eur J Immunol. 2020 Dec;50(12):1895-1911. (PMID: 32673408) Ann Palliat Med. 2020 Jul;9(4):1404-1412. (PMID: 32692208) Science. 2008 Nov 14;322(5904):1097-100. (PMID: 19008445) Front Immunol. 2022 Jan 14;12:808932. (PMID: 35095897) Sci Adv. 2021 Feb 5;7(6):. (PMID: 33547083) Hum Vaccin Immunother. 2022 Nov 30;18(6):2100189. (PMID: 36018753) Front Immunol. 2016 Jun 21;7:225. (PMID: 27446069) Sci Rep. 2022 Nov 18;12(1):19858. (PMID: 36400804) Proc Natl Acad Sci U S A. 2022 Mar 29;119(13):e2025607119. (PMID: 35320040) Nature. 2022 Mar;603(7901):493-496. (PMID: 35102312) Clin Transl Immunology. 2016 Mar 18;5(3):e66. (PMID: 27217957) Immunity. 2013 Jun 27;38(6):1164-75. (PMID: 23770227) Front Immunol. 2018 Sep 27;9:2169. (PMID: 30319629) J Immunol. 2015 Aug 1;195(3):1006-14. (PMID: 26101322) Immunology. 2017 Feb;150(2):146-154. (PMID: 27763656) JCI Insight. 2020 May 21;5(10):. (PMID: 32434994) mSphere. 2023 Feb 21;8(1):e0055822. (PMID: 36728430) Nat Microbiol. 2022 Nov;7(11):1756-1761. (PMID: 36195753) Cell Rep. 2022 Feb 15;38(7):110368. (PMID: 35123652) Proc Natl Acad Sci U S A. 2013 May 28;110(22):E2046-53. (PMID: 23580623) Transplantation. 2017 Apr;101(4):704-712. (PMID: 27906827) NPJ Vaccines. 2019 Jan 23;4:4. (PMID: 30701093) Pathogens. 2020 May 29;9(6):. (PMID: 32485970) Nat Rev Immunol. 2022 Apr;22(4):236-250. (PMID: 34312520) Eur J Immunol. 2015 Mar;45(3):854-64. (PMID: 25487143) Cell Rep. 2022 Aug 16;40(7):111214. (PMID: 35952673) J Immunol. 2020 Feb 1;204(3):510-517. (PMID: 31871021) J Immunol. 2011 Jul 15;187(2):842-50. (PMID: 21677141) |
| فهرسة مساهمة: | Keywords: COVID-19; Clec9A; antibody-dependent cytotoxicity; dendritic cell targeting; mucosal immunity; receptor binding domain; sarbecoviruses |
| المشرفين على المادة: | 0 (COVID-19 Vaccines) 0 (Lectins, C-Type) 0 (Antibodies, Viral) 0 (Antibodies, Neutralizing) 0 (Clec9a protein, mouse) 0 (Spike Glycoprotein, Coronavirus) 0 (Receptors, Mitogen) 0 (Receptors, Immunologic) |
| SCR Organism: | SARS-CoV-2 variants |
| تواريخ الأحداث: | Date Created: 20240508 Date Completed: 20240704 Latest Revision: 20240801 |
| رمز التحديث: | 20240801 |
| مُعرف محوري في PubMed: | PMC11286822 |
| DOI: | 10.1016/j.ymthe.2024.05.003 |
| PMID: | 38715364 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1525-0024 |
|---|---|
| DOI: | 10.1016/j.ymthe.2024.05.003 |